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Background: The burden of cancer is likely to increase among the human immunodeficiency virus (HIV)-positive
population as it ages due to successful antiretroviral therapy (ART). The purpose of this study was to determine the
risk of cancer in HIV-infected patients.
Methods: This study was a matched nested case–control study. It was performed using the National Health
Insurance Research Database of Taiwan. The control group included non–HIV-infected patients matched by sex,
age, and year of enrollment. Logistic regression analyses were performed and simultaneously adjusted for potential
confounders (income, urbanization, and Charslon index of comorbidity to evaluate HIV infection as an independent
risk of cancer. We calculated the overall and sex-specific standardized incidence ratios (SIR) to investigate the
pattern of cancer risk and overall cancer risk in the patients with HIV infection.
Results: Of the 1,115 HIV-infected patients, 104 (9.33%) developed cancer during the 11-year follow-up period. The risk of
cancer for patients with HIV infection was significant (adjusted odds ratio = 3.89, 95% confidence interval [CI] = 2.92–5.19)
after adjustment for potential confounders. There was a significantly increased risk of developing non-Hodgkin lymphoma
(SIR = 25.73, 95% CI = 6.83-90.85), cervical cancer (SIR = 4.01, 95% CI = 1.0-16.06), lymphoma (SIR = 20.26, 95% CI = 5.86-70.10),
and respiratory and intrathoracic cancer (SIR = 20.09, 95% CI = 2.34-172.09) compared with the control group. In addition,
HIV-infected patients were at significant risk for renal, oral, breast, liver, skin, and colorectal cancer.
Conclusions: Patients with HIV infection are at increased risk for several specific cancers. Our results support the
implementation of an active and accelerated cancer screening schedule for patients with HIV infection to
increase their life span.
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After use of combined antiretroviral therapy (cART),
highly active antiretroviral therapy has dramatically im-
proved the survival of human immunodeficiency virus
(HIV)-infected patients [1]. The substantial improvement
in survival after HIV infection has led to an increasing
clinical impact of long-term morbidities, including can-
cers, in this population. An increased risk of cancer has
been recognized in HIV-infected patients since the* Correspondence: jane2@tmu.edu.tw
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unless otherwise stated.beginning of the HIV epidemic [2,3]. This is believed
to be a result of HIV-induced immune suppression
hindering the control of cancer-associated viruses as
well as direct effects of HIV replication [4].
The incidence of acquired immunodeficiency syndrome
(AIDS)-defining cancers (ADCs) and non-AIDS-defining
cancers (NADCs) in HIV-infected patients has increased,
but the association between HIV infection and the risk of
cancer is both clinically and epidemiologically controversial
[1,5]. However, the burden of cancer, particularly NADCs,
is likely to increase as HIV-infected patients live longer [5].
Non-AIDS-related causes of morbidity and mortality are
becoming increasingly prevalent in HIV-infected patients,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mortality [6].
The rising incidence of cancer is a problem through-
out the world, including Taiwan. A cancer screening
protocol was implemented for the general population of
Taiwan by the Bureau of Health Promotion, Department
of Health, in 2010. Four types of cancers were targeted:
colorectal, breast, oral, and cervical. However, the preva-
lence of cancer in HIV-infected patients is still uncer-
tain, and the recommendations of a screening protocol
for HIV-infected patients are still being debated. The
purpose of this study was to elucidate the risk of cancer
in patients with HIV infection during the follow-up
period after diagnosis compared with patients without
HIV infection during the same period. We hope to apply
the findings of this study to a cancer prevention protocol
for the HIV-infected population.
Methods
Data collection
This matched nested case–control study was performed
using the National Health Insurance (NHI) Research
Database of Taiwan. The data set was obtained from the
Longitudinal Health Insurance Database (LHID) 2000 of
the NHI program, which was released by the Taiwan
National Health Research Institutes (NHRI) in 2013.
The NHI program started in Taiwan in 1996 and pro-
vides medical care for more than 99% of residents. For
the LHID 2000, the NHRI took a random sample of 1
million (4.2%) of the 23,753,407 people enrolled in the
NHI program and determined that there were no sta-
tistically significant differences in age, sex, and area
distribution between the subjects in the sampled group
and the original population. The LHID 2000 is a na-
tionwide population-based data set that provides out-
patient and inpatient claims for 11 years of follow-up
(since 2000) and therefore is an excellent resource for
evaluating the risk of cancer in patients with HIV infection.
Because the LHID data set consists of de-identified and
secondary data released to the public for research, the
study was exempt from full review by the Institutional
Review Board of Taipei Medical University.
Study population/case definition
We included data for all inpatients and outpatients
with HIV infection who received a diagnosis with the
International Classification of Diseases, Ninth Revision
(ICD-9-CM) code of 042 and filed claims, means the pa-
tients were diagnosed to have HIV infection, between
January 2000 and December 2011. This database was con-
structed with 1,000,000 persons derived from Taiwan’s
23,753,407 citizens. The period of follow-up was from
2000 to 2011. Only the study participants alive at the start
of follow up in 2000 were included in the study, and theywere followed for 11 years. However, the study partici-
pants (including HIV patients and controls) were cen-
sored when cancer developed, death occurred, or retrieval
from the National Health Insurance system. Our study in-
cluded 1,115 patients with HIV infection. The control
group was selected from the remaining people in the
LHID 2000. Because the participants with HIV infection
were distributed in a particular sex and age group, we ran-
domly selected participants without HIV infection for the
control group (4 controls for each HIV-infected partici-
pant) matched to the case group by sex, age, and year of
enrollment (year of HIV diagnosis).
We defined a participant with any type of cancer as
having a diagnosis with ICD-9-CM codes 140–208
except 166–169 and 177–178. Because the NHI Research
Database includes all medical service utilization for all
enrollees, we followed up all sampled participants and the
matched controls throughout the study period from 2000
to 2011. The stratification of urbanization was based on
the research of Liu et al., in which smaller numbers repre-
sent more urbanization [7].
The Charlson index of comorbidity was used to adjust
the comorbidities of these 2 groups. The comorbidity
index has been widely used for risk adjustment in chronic
diseases [8], and a list of 19 comorbidities was used to
produce a weighted index account for morbidity and mor-
tality rates. HIV/AIDS and malignancy were included in
the Charlson index and were the variables of interest in
our study; therefore, we used the modified Charlson index,
which excluded these 2 diseases.
Statistical analysis
The SAS 9.1 statistical package (SAS Institute Inc., Cary,
NC, USA) was used to perform all analyses in this study.
The Pearson chi-square test was used to examine the
differences in sociodemographic characteristics (monthly
income and urbanization) and potential confounders in
the modified Charlson index. Multiple logistic regression
analyses were performed and simultaneously adjusted
for the potential confounders of income and urbanization,
and the Charlson index was used to evaluate the inde-
pendent risk of cancer with HIV infection.
We calculated the overall and sex-specific standard-
ized incidence ratios (SIRs) to investigate the pattern of
cancer risk and overall cancer risk in the patients with
HIV infection. The SIRs were calculated by dividing the
actual observed number of cancer cases that occurred in
the patients with HIV infection by the expected number
of cancer cases. The expected number of cancer cases
was obtained from the number of cancer cases that
would occur in comparison group that corresponded to
the age-, gender-, and year of enrollment of HIV-infected
participants. Based on the Taiwan population census and
National Cancer Registry cancer registry data, we obtained
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stratum-specific incidence rates of cancers for the en-
tire population, respectively. We indicated “<0.5” if the
case number or expected number was less than 0.5 and
“N/A” with no calculation of SIR. The patient developing
more than one type of cancer was categorized to each type
of cancer. The patient with two occurrences of the same
type of cancer during the follow-up period was calculated
only once in the SIR. Crude and adjusted odds ratios
(ORs) are presented with 95% confidence intervals (CIs).
A two-sided P value ≤0.05 was considered statistically
significant.
Results
Figure 1 is a flow chart of the participants enrolled in the
study, and Table 1 shows the demographic characteristics
of the participants with HIV infection and the controlFigure 1 Study flow chart showing the selection of subjects. ICD-9-CM
immunodeficiency virus. LHID: longitudinal health insurance database.group. The ratio of male to female participants was about
3.0. The HIV-infected participants had lower monthly in-
come, less urbanization, and more comorbidities (higher
modified Charlson score) than those in the control group.
We calculated the mean follow-up times of the study par-
ticipants after enrollment. They were 55.53 months and
56.12 months, for the HIV-infected patients and controls,
respectively. The results are shown in Table 1.
The numbers of patients were diagnosed in each year
of enrollment were shown in Table 2. We finally enrolled
1,115 patients, of which 99.28% (1107) had received anti-
retroviral therapy.” Of the 1,115 patients with HIV infec-
tion, 104 (9.33%) developed cancer after diagnosis of
HIV infection during the follow-up period. The number
of subjects who were diagnosed with HIV at the same time
as the cancer was 48. The mean and range of duration of
infection (from HIV diagnosis to cancer diagnosis) for the: International Classification of Diseases, Ninth revision. HIV: human






No. (%) No. (%) P-value
Age 1
≦24 137 (12.3) 548 (12.3)
25 – 44 626 (56.1) 2,504 (56.1)
45 – 64 202 (18.1) 808 (18.1)
≧65 150 (13.5) 600 (13.5)
Gender 1
Male 836 (75) 3,344 (75)
Female 279 (25) 1,116 (25)
Monthly income <0.001
NTD 0 ~ 17280 502 (45) 1,355 (30.4)
NTD 17281 ~ 28800 399 (35.8) 1,624 (36.4)
NTD ≥28801 279 (19.2) 1481 (33.2)
Urbanization level <0.001
1 355 (31.8) 1,291 (29)
2 313 (28.1) 1,412 (31.7)
3 210 (18.8) 891 (20)
4 139 (12.5) 538 (12.1)
5 22 (2) 78 (1.8)
6 35 (3.1) 126 (2.8)
7 41 (3.7) 124 (2.8)
Modified Charlson score <0.001
0 29 (2.6) 1,644 (36.8)
1-5 1011 (90.7) 2638 (59.2)







Cancer 104 (9.3) 119 (2.7) <0.001
Modified Charlson index: Charlson index excluding HIV/AIDS, malignancy.
SD: standard deviation.
Q1: first interquartile, Q3: third interquartile.
Table 2 The year of enrollment of HIV-infection patients
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subjects may have had the HIV infection for a while prior
to diagnosis, hence this time would be an underestimate.
Table 3 shows that age was a significant risk factor for de-
veloping cancer and the risk gradually increased with
older age (≥65 years old; adjusted OR = 32.13) after ad-
justment for multiple confounders. Furthermore, male
gender was more significantly associated with cancer
than female gender (adjusted OR= 1.45, 95% CI = 1.06–1.99)
after adjustment for other risk factors, and a highly modified
Charlson score was significantly associated with cancercompared with a low Charlson score (adjusted OR= 7.66,
95% CI = 4.83–13.4) after adjustment. However, the risk of
cancer for patients with HIV infection was significant
(adjusted OR = 3.89, 95% CI = 2.92–5.19) after adjust-
ment for the previously described confounders, such as
age, sex, monthly income, urbanization, and modified
Charlson score.
We further analyzed the site-specific risk of cancer be-
tween patients with HIV infection and those without HIV
infection (Table 4). Among the ADCs, non-Hodgkin
lymphoma (SIR = 25.73, 95% CI = 6.83-90.85), and cervical
cancer (SIR = 4.01, 95% CI = 1.0-16.06) show significant
increase of the SIR between those with HIV infection
and comparison group. Lymphoma (SIR = 20.26, 95%
CI = 5.86-70.10), and lung cancer (SIR = 3.49, 95% CI =
1.66-7.37) show significant increase of SIR between
those with HIV infection and comparison group. We
examined SIR of cancer within the follow-up period
and found that renal (SIR = 4.82, 95% CI = 1.47-15.83),
oral cancer (SIR = 3.29, 95% CI = 1.36-7.96), breast cancer
(SIR = 4.01, 95% CI = 1.16-13.89), liver cancer (SIR = 3.75,
95% CI = 1.76-7.99), skin cancer (SIR = 3.44, 95% CI =
1.15-10.26), and colorectal cancer (SIR = 2.21, 95% CI =
1.06-4.63) were significantly increased risk between
those with HIV infection and comparison group. The
duration of infection was different by cancer site, the
longest duration was cancers of bone and connective
tissue (42.44 ± 39.51 months), the shortest duration
was lymphoma (17.91 ± 18.17 months). There were 25
and 35 patients had multiple cancers in the HIV-infection
and non-HIV groups, respectively.
Although the risk of occurrence of Kaposi’s sarcoma
cannot be calculated by SIR due to the 0% occurrence in
the control group, the association of Kaposi’s sarcoma
with HIV infection was very strong (n = 12).
Table 3 Logistic regression and multivariate adjusted odds
ratios of the cancer risk with different variables
Variable Crude OR (95% CI) Adjusted ORa (95% CI)
HIV
No 1 1
Yes 3.75 (2.86 ~ 4.93)** 3.89 (2.92 ~ 5.19)**
Age
≦24 1 1
25 – 44 3.44 (1.25 ~ 9.49)** 3.14 (1.12 ~ 8.83)*
45 – 64 12.09 (4.39 ~ 33.33)** 11.85 (4.18 ~ 35.57)**
≧65 23.21 (8.48 ~ 63.55)** 32.13 (10.78 ~ 95.75)**
Gender
Female 1 1
Male 0.72 (0.54 ~ 1.96) 1.45 (1.06 ~ 1.99)*
Monthly income
NTD 0 ~ 17280 1 1
NTD 17281 ~ 28800 0.54 (0.40 ~ 0.74)** 0.85 (0.60 ~ 1.19)
NTD ≥28801 0.35 (0.24 ~ 0.50)** 0.90 (0.58 ~ 1.41)
Urbanization level
1 1 1
2 1.23 (0.86 ~ 1.77) 1.11 (0.76 ~ 1.63)
3 1.05 (0.69 ~ 1.61) 0.93(0.59 ~ 1.45)
4 1.85 (1.22 ~ 2.82)** 1.44 (0.92 ~ 2.26)
5 0.91 (0.28 ~ 2.97) 0.46 (0.13 ~ 1.64)
6 1.14 (0.48 ~ 2.69) 0.63 (0.24 ~ 1.62)
7 2.52 (1.35 ~ 4.73)** 1.58 (0.79 ~ 3.18)
Modified Charlson score
0 1 1
1 ~ 5 2.63 (2.32 ~ 9.08)** 1.73 (1.45 ~ 3.62)**
≧6 11.96 (6.92 ~ 20.67)** 7.66 (4.83 ~ 13.4)**
*P < 0.05, **P < 0.001.
a Adjusted with age, gender, income, urbanization, modified Charlson index.
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To the best of our knowledge, this is a first nationwide,
population-based, follow-up study showing that HIV-
infected patients are at significant risk for many types of
cancers, such as oral cancer, gastrointestinal cancer, re-
spiratory and intrathoracic cancer, bone and connective
tissue cancer, genitourinary cancer, lymphoma, and cen-
tral nervous system cancer. Although our control group
was age- and sex-matched with the case group, our
study also showed that age and sex were independent risk
factors for cancer after adjustment for HIV infection.
Our results showed that there is a significantly higher
rate of NADCs occurring in HIV-infected versus non–
HIV-infected patients. Our findings are in agreement
with those of a study by Cooley, which showed an increase
of NADCs in HIV-infected patients [9]. Furthermore, we
demonstrated the increased occurrence of many specificcancers in HIV-infected patients. HIV-infected patients
have an elevated risk for certain NADCs [1], which is
largely attributable to loss of control of the oncogene
group and a high prevalence of exposure to other carcino-
gens [10]. It is possible that either acceleration of carcino-
genesis by HIV infection or earlier exposure to risk factors
for cancer play a role [1]. The mechanism underlying the
association between HIV infection and cancer is still
unclear.
Breast cancer is one of the most common malignan-
cies in women in the general population [11]. A large
registry linkage study of cART-era data showed that the
risk of breast cancer in HIV-infected women now mirrors
that of the general population [12]. Studies from different
populations or health care systems have provided incon-
sistent findings [9,11,12], and the data on the incidence
and prognosis of breast cancer in HIV-infected patients
are limited and conflicting [13-15]. One study reported on
the possible mechanisms of environmental pollution and
breast cancer [16], and HIV-infected patients seem to be
vulnerable to these mechanisms. There may be multiple
factors related to the development of breast cancer in
these patients, such as low income, low socioeconomic
status (SES), and poor lifestyle. However, our data show
an increased risk for breast cancer in those with HIV in-
fection. A recent nested case–control study from the
Women’s Interagency HIV Study and HIV Epidemiology
Research Study cohorts showed that a low risk of breast
cancer may be linked to infection with CXCR-4 tropic
virus [17]. This demonstrated lower risk was observed in
the pre-cART era but not in the cART era [18]. It may ex-
plain why our HIV-infected patients, who decreasing
CXCR-4 protective effect after using cART, had higher in-
cidence of breast cancer. Future studies may be needed to
explore it. Patients in Taiwan with breast cancer are
younger (median age of 45 years) than those in Western
countries [19,20], and the molecular subtypes of breast can-
cer in Taiwan differ from those in Western countries [21].
Nevertheless, our findings should remind HIV-infected pa-
tients, especially young patients, to examine their breasts
regularly for the possibility of breast cancer.
Skin cancers, in particular basal cell carcinoma, are
the most common malignancies in the general popula-
tion [22]. In our study, the SIR of skin cancer indicated
a significantly increased risk in those with HIV infection
compared with the control group. HIV-infected patients
seem to be vulnerable to skin cancer, and this may be at-
tributed to multiple factors, such as high exposure to
ultraviolet rays, low SES, and poor lifestyle. Nevertheless,
our data support an increased risk for skin cancer in
those with HIV infection.
Lung cancer is the most common cause of cancer
mortality worldwide [23] and is the third most common
malignancy in HIV-infected patients [1,24,25], but lung
Table 4 SIR of site-specific cancer of the HIV-infection patients group in different gender and overall population
Men Women All
Cases of cancer Cases of cancer Cases of cancer
Cancer site Observed Expected SIR (95% CI) Observed Expected SIR (95% CI) Observed Expected SIR (95% CI)
ENT (140–149) 10 4 3.15***
(1.38 ~ 7.20)
1 <0.5 N/A 11 4 2.77***
(1.28 ~ 5.98))
Oral (140–146) 8 2.75 4.09***
(1.53 ~ 10.93)
1 <0.5 N/A 9 2.75 3.29***
(1.36 ~ 7.96)
Non- Oral (147–149) 2 2.25 0.85 (0.27 ~ 6.72) <0.5 <0.5 N/A 2 2.25 0.89 (0.19 ~ 4.12)
GI (150 ~ 159) 20 7 2.99***
(1.69 ~ 5.27)
10 5 1.96 (0.77 ~ 3.41) 30 12 2.54***
(1.60 ~ 4.06)
Liver (155) 11 3 3.76***
(1.65 ~ 8.55)
2 1.5 1.15 (0.35 ~ 2.43) 13 4.5 3.75***
(1.76 ~ 7.99)





3 2.25 1.36 (0.75 ~ 3.01) 8 4 2.01 (0.86 ~ 4.70)
Anus (154.2-154.8) <0.5 <0.5 N/A 1 <0.5 N/A 1 <0.5 N/A


















4 <0.5 N/A 1 <0.5 N/A 5 <0.5 N/A
Bone,connective tissue
(170–176)




Breast (174–175) 1 <0.5 N/A 4 1.25 2.80***
(1.29 ~ 10.01)
5 1.25 4.01* (1.16 ~ 13.89)
Skin & soft tissue
(170–173)
2 <0.5 N/A- 4 1.5 8.44***
(1.54 ~ 46.32)
6 1.75 3.44* (1.15 ~ 10.26)
Malignant melanoma of
skin (172)
<0.5 <0.5 N/A <0.5 <0.5 N/A <0.5 <0.5 N/A
Other skin & soft tissue
(170, 171, 173)
2 <0.5 N/A 4 1.5 8.44***
(1.54 ~ 46.32)
6 1.75 3.44* (1.15 ~ 10.26)
Kaposi (176) 12 <0.5 N/A <0.5 <0.5 N/A 12 <0.5 N/A
Bone (170) <0.5 <0.5 N/A <0.5 <0.5 N/A <0.5 <0.5 N/A










2 0.75 2.15 (0.87 ~ 8.65) 6 1.25 4.82***
(1.47 ~ 15.83)
Cervical (180) <0.5 <0.5 N/A 4 1 4.01* (1.0 ~ 16.06) 4 1 4.01* (1.0 ~ 16.06)
Others (179,181-187) 4 1.25 2.71 (0.76 ~ 9.64) 5 2.5 2.75***
(1.21 ~ 6.25)
9 3.75 2.41* (1.05 ~ 5.53)
Lymphoma (200–203) 12 0.75 12.22***
(3.08 ~ 36.12)







3 0.77 3.90(0.73 ~ 9.55) 13 0.5 25.73***
(6.83 ~ 90.85)
Leukemia (204–208) 1 1 1.00 (0.10 ~ 8.96) <0.5 <0.5 N/A 1 1 1.00 (0.10 ~ 8.96)
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Table 4 SIR of site-specific cancer of the HIV-infection patients group in different gender and overall population (Continued)
CNS (190–192) 2 <0.5 N/A 3 <0.5 N/A 5 <0.5 N/A
Thyroid (193) <0.5 <0.5 N/A 2 <0.5 N/A 2 1 2.01 (0.37 ~ 10.94)
Others (194–199) 6 4 2.05 (0.76 ~ 3.99) 6 3.25 1.76 (0.89 ~ 6.16) 12 7.25 1.66 (0.85 ~ 3.37)
SIR: standardized incidence ratios.
ENT: ear-nasal cavity-throat.




N/A: no calculation of SIR due to case number or expected number less than 0.5.
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be clearly associated with immunodeficiency or AIDS-
related pulmonary disease [26]. In our study, the SIR of
lung cancer indicated a significantly increased risk be-
tween HIV-infected and non–HIV-infected patients;
HIV-infected patients seem to be vulnerable to lung can-
cer, and this may be attributed to multiple factors, such
as smoking, air pollution, low SES, and poor lifestyle.
However, our data support an increased risk of lung can-
cer in those with HIV infection.
In Taiwan, oral cavity cancer was the fifth most preva-
lent cancer in 2008 [27]. The risk factors for oral cancer
include smoking, alcohol consumption, race, chewing of
betel leaves and areca nuts, and low SES [28]. HIV RNA
and human papillomavirus (HPV) DNA are present in
the oral cavity of HIV-positive patients, and the virus-
related pathology has been studied [29]. Chaiyachati re-
ported on 2 HIV-infected patients who first developed
HPV-related anal squamous cell carcinoma and later
oral squamous cell carcinoma [30]. Our study showed
that HIV-infected patients have a significant risk of de-
veloping oral cancer and cervical cancer. It is possible
that oral sex could play an important role in explaining
these results in addition to the viral biological effect.
The prevention of oral cancer is an integral part of our
national cancer-control programs, and we must ensure
that HIV-infected patients undergoing screening. If a
clinician knows a patient with HIV infection, he/she is
more likely to look for AIDS-defining cancers according
to the guidelines in 2014 [31].
Our study showed that HIV-infected patients are at
significant risk for developing cancer of the gastrointes-
tinal tract. This type of cancer is one type of NADC with
various malignancies, included colorectal cancer and
liver cancer [9,32,33]. However, the existing data suggest
that colorectal cancer develops at a younger age, at an
advanced stage, and with an unfavorable prognosis in
the HIV population [28]. There have also been reports
of various etiologic agents, including genetic agents, im-
munologic agents, and viruses such as HPV, playing a
role in the development of colorectal cancer in this
HIV-infected population, which is different from the
general population [34,35]. Liver cancer is the fifth mostcommon cancer worldwide [36], and chronic hepatitis C
and hepatitis B virus infections are the main risk factors
for development of liver cancer. HIV coinfection has
been shown to increase the progression of liver fibrosis
[37,38] and is likely to eventually increase the incidence
of the tumor [33]. Anal cancer, cervical cancer, and liver
cancer are each associated with coinfections (i.e., HPV
for anal cancer and cervical cancer, and hepatitis B and
C viruses for liver cancer), and the risks of these cancers
in HIV-infected individuals are increased because of a
greater prevalence of coinfection (for HPV and the hepa-
titis viruses) and an inability to control these infections
with a suppressed immune system [39]. Our data sup-
port an increased risk of colorectal cancer and liver can-
cer in those with HIV infection. We suggest that the
HIV population should be considered a high-risk group
and screened accordingly, with reduced intervals be-
tween pap smears, ultrasonography, or colonoscopy.
Our study has several strengths. Most importantly, the
Taiwan NHI includes data from a longitudinal cohort
and is a large and population-based database. The na-
tionwide LHID 2000 provided an excellent resource for
evaluating the risk of cancer in patients with HIV infec-
tion, so our study is valuable for establishing a cancer
screening program for HIV-infected patients. Neverthe-
less, a number of limitations should be considered when
interpreting our findings. First, HIV infection status is
not indicated on health insurance cards, and a few pa-
tients with HIV infection have not been reported to the
Taiwan Centers for Disease Control because of hospital
shopping. Therefore, the data from the Centers for Dis-
ease Control on reported communicable diseases is not
synchronized with the data set of the NHI program. We
thought that the data set from the NHI program was
more accurate because of those patients with HIV infec-
tion who have not been reported to the Taiwan Centers
for Disease Control. And, the duration of HIV infection
could be possibly underestimated in this study. Second,
there was a lack of information about some risk behav-
iors, including personal habits, smoking, and lifestyle,
which may not allow direct assessment of exposure to
risk factors for known cancer. Third, there were no la-
boratory data on the CD4 cell count recorded in the
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mine how severe the HIV infections were in our study
patients. The latest limitation, although we obtained
99.28% of the enrolled 1,115 HIV-infected patients had
received ART, the percentage of HIV-infected patients
receiving ART at the time of cancer diagnosis can not be
obtained in this database.
Conclusions
This study found that patients with HIV infection had a
significantly higher risk of developing cancer compared
with patients without HIV infection, especially breast
cancer, oral cancer, colorectal cancer, liver cancer, re-
spiratory and intrathoracic cancer, bone and connective
tissue cancer, genitourinary cancer, lymphoma, and cen-
tral nervous system cancer. Our results support an active
and accelerated screening schedule in patients with HIV
infection for breast, oral, colorectal, liver, and cervical
cancer. However, patients with HIV infection should still
undergo regular screenings for cancer based on the rec-
ommendations for the general population. Moreover,
specific screening guidelines for cancer should be estab-
lished for patients with HIV infection to increase their
quality of life and life span.
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